Specialties

Diabetic retinopathy remains one of the leading causes of preventable blindness worldwide. Yet despite clear screening guidelines, many patients with diabetes still miss their annual retinal exams. Busy schedules, limited specialist access, transportation barriers, and lack of awareness often delay diagnosis until vision changes become permanent. As healthcare systems search …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …

For many patients with obesity-related osteoarthritis, daily movement can feel like walking with a heavy backpack that never comes off. Joint pain limits exercise, reduced activity leads to more weight gain, and the cycle continues. However, new research is raising an important question: could GLP-1 therapies help break that cycle? …

What if a medication designed to lower blood sugar could also help protect the brain? That question is driving growing interest among researchers studying the connection between GLP-1 drugs and Parkinson’s disease. Scientists are now exploring whether therapies originally developed for type 2 diabetes and obesity may influence inflammation, neuronal …

Choosing the right treatment for patients with both diabetes and heart disease can feel like walking a tightrope. With evolving evidence, the role of incretin therapy in cardiovascular disease management is now at the center of clinical decision-making. Recent cardiovascular outcomes trials have shifted how clinicians think about therapy selection, …

Can we actually prevent type 1 diabetes before symptoms appear? Increasingly, the answer is yes. As research evolves, clinicians now have stronger tools to identify at-risk children earlier and delay disease progression. This shift is especially important because type 1 diabetes often develops silently before diagnosis. Therefore, early screening and …

Managing hyperglycemia in oncology patients is becoming a critical part of cancer care, especially as newer therapies affect glucose metabolism. Have you ever wondered why patients with no history of diabetes suddenly develop high blood sugar during treatment? This growing challenge highlights the need for structured, practical approaches. In this …

In recent years, the role of incretin therapy in cardiovascular disease management has gained attention as new outcomes data reshape how clinicians approach high-risk patients. But should treatment choices really change based on these findings? As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular …

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …